NRD
TNDM icon

Nebula Research & Development’s Tandem Diabetes Care TNDM Stock Holding History

Nebula Research & Development’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,980
Closed -$241K – 1167
2024
Q2 		$241K Buy
+5,980
New +$249K 0.04% 676

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's TNDM Position: Q3 2024 in Review

Nebula Research & Development sold out of Tandem Diabetes Care (TNDM) in Q3 2024, closing a stake of 5,980 shares — an estimated $241K sold.

Nebula Research & Development first reported a position in TNDM in Q2 2024 and held it in 1 quarter. The position peaked at $241K in Q2 2024. 332 funds tracked by Wall St. Rank hold TNDM as of Q3 2024.

  • Nebula Research & Development reported no remaining Tandem Diabetes Care position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 5,980 Tandem Diabetes Care shares in Q3 2024, an estimated $241K.
  • Nebula Research & Development first reported a position in Tandem Diabetes Care in Q2 2024 and held it in 1 quarter.
  • Nebula Research & Development's Tandem Diabetes Care position peaked at $241K in Q2 2024.
  • 332 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.